• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Atopic Dermatitis - Articles and news items

atopic-dermatitis

Success for Regeneron and Sanofi’s atopic dermatitis trial

Industry news / 5 October 2016 / Niamh Louise Marriott, Digital Content Producer

Two placebo-controlled Phase 3 trials, evaluating dupixent in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD)…

leo pharma

AstraZeneca licenses skin disease drugs to LEO Pharma

Industry news / 1 July 2016 / Victoria White, Digital Content Producer

AstraZeneca has entered into an agreement with LEO Pharma for the global licence to tralokinumab in skin diseases.

anacor

Pfizer completes acquisition of Anacor Pharmaceuticals

Industry news / 27 June 2016 / Victoria White, Digital Content Producer

The Anacor acquisition adds crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, to Pfizer’s pipeline…

Dupilumab

Dupilumab + TCS superior to TCS alone in treating atopic dermatitis

Industry news / 6 June 2016 / Victoria White, Digital Content Producer

Sanofi and Regeneron have announced that a Phase III study evaluating dupilumab in atopic dermatitis met its primary and key secondary endpoints…

Positive top-line Phase IIa trial results for DS107 as a treatment for atopic dermatitis

Positive top-line Phase IIa trial results for DS107 as a treatment for atopic dermatitis

Industry news / 7 January 2016 / Nicholas Jackson

DS Biopharma has announced positive top-line Phase IIa trial results for DS107 as an oral treatment for moderate to severe atopic dermatitis…

atopic-dermatitis

Black Swan Analysis has added to its Epiomic Epidemiology series of reports with Atopic Dermatitis forecast in 17 major markets 2015-2025

Supplier news / 1 December 2015 / Black Swan Analysis

Research and Markets has announced the addition of the “Epiomic Epidemiology Series: Atopic Dermatitis Forecast in 17 Major Markets 2015-2025” report to their offering…

atopic-dermatitis

Atopic dermatitis treatment market to more than double in value

Industry news / 19 November 2015 / Victoria White

GlobalData states that this increase will be driven primarily by the 2017 launch of the first biologic for the treatment of moderate to severe disease, dupilumab…

eczema

Researchers beat untreatable eczema with arthritis drug

Industry news / 20 July 2015 / Victoria White

Researchers have successfully treated patients with moderate to severe eczema using an arthritis drug recently shown to reverse two other skin conditions…

crisaborole

Anacor’s crisaborole achieves primary and secondary endpoints in two Phase 3 studies in eczema

Industry news / 13 July 2015 / Victoria White

Anacor has announced positive preliminary top-line results from its two Phase 3 pivotal studies of crisaborole in atopic dermatitis (eczema)…

GlobalData

US sales of Sanofi/Regeneron’s Dupilumab for atopic dermatitis could exceed $1.3 Billion by 2022, says GlobalData Analyst

Industry news / 4 December 2014 / GlobalData

The first biologic to treat atopic dermatitis, Sanofi and Regeneron’s dupilumab, could launch in the US by Q2 2017, and the potentially game-changing drug could achieve annual sales of over $1.3 billion in this market by 2022, according to an analyst with research and consulting firm GlobalData…

Sanofi

Sanofi and Regeneron announce positive results from Phase 2b study of Dupilumab in patients with moderate-to-severe atopic dermatitis

Industry news / 10 July 2014 / Sanofi

Sanofi and Regeneron Pharmaceuticals, Inc. announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis, a serious, chronic form of eczema…

SANOFI logo

Sanofi and Regeneron’s Dupilumab named “Clinical Advance of the Year” by Scrip Intelligence

Industry news / 25 November 2013 / Sanofi

Dupilumab is a fully-human monoclonal antibody that is in clinical development for treatment of asthma, atopic dermatitis, and nasal polyposis…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +